CTOs on the Move


 
Founded in 2016, Huupe is the first-ever smart basketball hoop. It brings competition and training to basketball enthusiasts and players, including NBA athletes as well as stars from the league who have invested in the company. Huupe`s groundbreaking innovation enables ages eight and up to compete on the court or virtually, learn and improve their skills, track their progress, and more. The appointment of Paul as CTO follows the company`s 400% growth month over month in the past six months this year, with 50% growth in October 2022 alone, and viral popularity on social media.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Welcome Nursing Home Inc

Welcome Nursing Home Inc is a Oberlin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Health Center of the North Country

Community Health Center of the North Country is a healthcare provider with locations in St. Lawrence, Franklin, and Jefferson counties in Northern New York. They offer comprehensive primary, pediatric, behavioral, dental, optometry, and preventative ca...

Lavie Administrative Services

Lavie Administrative Services is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

North Central Connecticut EMS Council Inc

North Central Connecticut EMS Council Inc is a Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.